The Healthy Microbiome and Chronic Diseases group focuses on understanding the role of the microbiome as a mediator of systemic host regulation including metabolic, immune and neurological responses.
Through intervention trials, the group investigates the relationship between the microbiome and health outcomes. The group employs metagenomics, gnotobiotic-based preclinical models and molecular approaches as a foundation for precision analysis, with specific clinical foci on metabolic diseases, urogynaecological and neurodegenerative conditions.
The group engages in clinical and industry partnerships for microbiome-based discovery studies to predict risk and identify therapeutic strategies.
